Is BPC-157 illegal in Australia? Schedule 4, TGA, WADA and FDA status

Is BPC-157 illegal in Australia?

BPC-157 is a prescription-only (Schedule 4) substance in Australia. The Poisons Standard also lists it at item 5 of Appendix D, clause 5, a table of poisons that 'must not be possessed by a person without authority (for example, possession other than in accordance with a legal prescription)'. Those words come from the October 2026 instrument, F2026L01327, read on 14 October 2026 on legislation.gov.au. The TGA's advisory of 13 April 2026 adds that state and territory laws may impose further controls on the sale, supply and possession of unapproved peptide products. These entries are classifications, not a verdict on any person's situation.

Schedule 4 is the prescription-only tier. Appendix D is a second list, for poisons where possession itself carries a condition. A # beside a Schedule 4 entry means the same substance is also in Appendix D, and BPC-157's entry carries it. The Schedule 4 and Appendix D explainer walks through both lists, and the Australian law hub sets BPC-157 beside the other catalogue peptides. Western Australia adds its own layer, set out in how the Poisons Standard reaches Western Australia.

A plain yes or no would be easy to write and wrong to publish. A classification describes a substance. A person's position depends on what they do, who authorised it and where they live. This page therefore stops at what the documents say.

Evidence limits

What do these legal records not tell you?

The FDA material further down is a United States record, not an Australian one. It is included because people ask about it. A committee vote in Washington does not change the Schedule 4 entry in Canberra.

This page did not query the TGA's ARTG search tool (the Australian Register of Therapeutic Goods, the national register of therapeutic goods), so it reports no ARTG search result as at 14 October 2026. The status described below rests on the TGA's own statement that examples of unapproved peptide products include BPC-157.

What did the TGA decide about BPC-157 in 2024?

The TGA's delegate (the official who makes scheduling decisions) decided to create a new Schedule 4 entry and a new Appendix D, clause 5 entry for BPC-157, with an implementation date of 1 June 2024 (TGA notice of final decisions, published 22 May 2024). The notice says the proposal responded to 48 referrals for importation of BPC-157 received by the TGA since 1 July 2022, that it sought to 'align the scheduling of BPC-157 with other performance- and image-enhancing substances', and that BPC-157 was not then captured in the Poisons Standard.

Think of it as a paper trail. A proposal went to the 43rd meeting of the Advisory Committee on Medicines Scheduling in November 2023. The delegate published an interim decision on 3 April 2024, then confirmed it. The notice lists 22 public submissions on the proposal and one on the interim decision, which it describes as supportive (TGA notice, 22 May 2024).

The October 2026 edition of the Poisons Standard carries the entry forward as '# BPC-157.' in Schedule 4 and as item 5 in Appendix D, clause 5 (instrument F2026L01327, read 14 October 2026).

What has the TGA said about BPC-157 products?

The TGA's safety advisory of 13 April 2026 names BPC-157 among examples of unapproved peptide products, meaning goods not included in the ARTG. The advisory says these products 'have not been evaluated for safety, quality or effectiveness by the TGA' and that a 'research use only' disclaimer does not make supply lawful. The TGA's peptide products page, modified 23 September 2026 and read 14 October 2026, says that if the TGA identifies serious non-compliance, regulatory action may include import interventions, product seizures, infringement notices and civil or criminal penalties.

The advisory says a research-use-only disclaimer does not change a product's regulatory status, permit importation or remove advertising or supply obligations. The catalogue lists BPC-157 laboratory reference material as research material. Research material is not an approved medicine, and a label does not alter the legal records described here.

An ARTG entry applies to a product. A Schedule entry classifies a substance. The two answer different questions, which the comparison table below keeps apart.

Is BPC-157 on the WADA Prohibited List?

BPC-157 is named in class S0 (non-approved substances) of the World Anti-Doping Agency's 2026 Prohibited List, which states that it comes into effect on 1 January 2026. S0 substances are prohibited at all times, in and out of competition, and every S0 substance is a Specified Substance, a sub-group label in the World Anti-Doping Code (WADA 2026 List, checked 14 October 2026). The list says S0 'covers many different substances including but not limited to BPC-157'. The status is a sport rule. It is separate from the Poisons Standard.

S0 is a catch-all. It covers any pharmacological substance that no later section of the List addresses and that has no current approval from a governmental regulatory health authority for human therapeutic use. BPC-157 is the first example the List names in that class. The class is defined in the same PDF.

TB-500 sits under a different heading. The 2026 List names 'Thymosin-ß4 and its derivatives e.g. TB-500' in S2.3, growth factors and growth factor modulators, and S2 is also prohibited at all times. A search for both names therefore finds one shared status and two separate entries.

What does Sport Integrity Australia say about BPC-157?

Sport Integrity Australia (SIA), the Australian agency that publishes anti-doping guidance, lists BPC-157 among common examples of unapproved peptides that are prohibited in sport (SIA, 'Peptides explained', read 14 October 2026). SIA says that possession or use of prohibited peptide products by athletes can result in an anti-doping rule violation and significant consequences, including a ban from sport. It also says that a Therapeutic Use Exemption is unlikely to be granted for an unregistered medicine, such as a compounded product the TGA has not approved. SIA's page describes a sport rule and does not classify the substance under the Poisons Standard.

SIA notes that unapproved peptides are sold labelled 'research chemicals' or 'not for human consumption', and that most research into their toxicity is in animal models, with results being interpreted for human use. The agency's own page carries any later update.

A sport listing, a Schedule entry and an ARTG entry can each be checked in a few minutes, and each answers a different question. None of them predicts the others.

Is BPC-157 FDA approved?

According to the US Food and Drug Administration's briefing document, whose BPC-157 review is dated 11 May 2026, BPC-157 is not a component of an FDA-approved drug. The review also states that no applicable United States Pharmacopeia or National Formulary monograph exists for BPC-157. It reports that a globalEDGE search did not yield BPC-157 as a component of an approved product in any country, and that no monograph exists in the European (11th edition), Japanese (18th edition) or International (12th edition) Pharmacopoeias. The review was written for an advisory committee on compounding, which is a separate question from drug approval.

Compounding is the preparation of a medicine for an individual by a licensed pharmacist or physician from bulk ingredients, instead of supplying a manufactured, approved product. Section 503A of the US Federal Food, Drug, and Cosmetic Act sets the conditions, including which bulk ingredients may be used. The review evaluated BPC-157 against that list, the 503A Bulks List, and not against approval as a drug (FDA briefing document, July 2026).

What has the FDA said about BPC-157 in compounded drugs?

The FDA's page on bulk drug substances that may present significant safety risks, dated 22 April 2026, lists immune-reaction risks, peptide-related impurities and uncertainty about ingredient identity for compounded BPC-157 products. The FDA says the safety information available for the proposed product forms is absent or limited and insufficient to determine human harm. BPC-157 appears on that page's list of nominated but withdrawn substances, previously in category 2 (FDA, 22 April 2026). These are regulator concerns, not measurements of how often a reaction occurs.

Immunogenicity means the chance that the body makes antibodies against a peptide. The review team's May 2026 conclusions were that BPC-157 is not well characterised from a physicochemical perspective, that its search found no studies of BPC-157 in people for the routes assessed in that review, and that clinical safety information is insufficient to characterise a safety profile. The team's proposal was that neither BPC-157 free base nor BPC-157 acetate be added to the 503A Bulks List (FDA briefing document).

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee met to discuss BPC-157. The Regulatory Affairs Professionals Society reported the same day that the committee "voted 8-6 with one abstention" to recommend that two peptides, BPC-157 for ulcerative colitis and KPV, be added to the 503A Bulks List (RAPS, 23 July 2026). The FDA's meeting page carries no vote result and says advisory committees make non-binding recommendations. The FDA's briefing document says the agency will not issue a final determination until the committee's input has been considered and all reviews are finalised. None of the FDA pages read for this page, on 14 October 2026, records a final determination.

How do scheduling, ARTG status and sport bans differ for BPC-157?

Scheduling, ARTG status and sport bans are three separate records about BPC-157. The Poisons Standard classifies the substance by control level, and BPC-157 has a Schedule 4 entry and an Appendix D listing. The ARTG lists products the TGA has included on the register, and the TGA names BPC-157 products as unapproved. The WADA List and Sport Integrity Australia concern sport, where BPC-157 is prohibited at all times. A change in one record does not change the others (records read 14 October 2026).

Imagine three different offices, each with its own filing cabinet. One files substances by risk. One files products by approval. One files substances by sport. The same name can sit in all three cabinets and mean something different in each. The table below shows the eight records side by side.